---
title: "Novartis and Takeda drugs gain rare blood cancer routine use on NHS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293229662.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-20T10:46:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293229662.md)
  - [en](https://longbridge.com/en/news/293229662.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293229662.md)
---

# Novartis and Takeda drugs gain rare blood cancer routine use on NHS

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track | TAK Stock News](https://longbridge.com/en/news/294314267.md)
- [Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept Phase 3 dosing](https://longbridge.com/en/news/294408894.md)
- [Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use](https://longbridge.com/en/news/294363759.md)
- [Evommune begins Phase IIb trial of EVO756 for migraine](https://longbridge.com/en/news/294503057.md)
- [GSK eyes future growth with cost-cutting plan amid promising Q2](https://longbridge.com/en/news/294228897.md)